195 related articles for article (PubMed ID: 35834843)
1. Lurbinectedin shows clinical activity and immune-modulatory functions in patients with pre-treated small cell lung cancer and malignant pleural mesothelioma.
Dumoulin DW; Cantini L; Cornelissen R; Vink M; Klaase L; Slooff K; Tebayna N; Mankor JM; Baart SJ; Hendriks R; Dingemans AC; Willemsen M; Aerts JGJV
Eur J Cancer; 2022 Sep; 172():357-366. PubMed ID: 35834843
[TBL] [Abstract][Full Text] [Related]
2. Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16).
Metaxas Y; Früh M; Eboulet EI; Grosso F; Pless M; Zucali PA; Ceresoli GL; Mark M; Schneider M; Maconi A; Perrino M; Biaggi-Rudolf C; Froesch P; Schmid S; Waibel C; Appenzeller C; Rauch D; von Moos R;
Ann Oncol; 2020 Apr; 31(4):495-500. PubMed ID: 32085891
[TBL] [Abstract][Full Text] [Related]
3. Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study.
Mark M; Rusakiewicz S; Früh M; Hayoz S; Grosso F; Pless M; Zucali P; Ceresoli GL; Maconi A; Schneider M; Froesch P; Tarussio D; Benedetti F; Dagher J; Kandalaft L; von Moos R; Tissot-Renaud S; Schmid S; Metaxas Y
ESMO Open; 2022 Jun; 7(3):100446. PubMed ID: 35427834
[TBL] [Abstract][Full Text] [Related]
4. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.
Trigo J; Subbiah V; Besse B; Moreno V; López R; Sala MA; Peters S; Ponce S; Fernández C; Alfaro V; Gómez J; Kahatt C; Zeaiter A; Zaman K; Boni V; Arrondeau J; Martínez M; Delord JP; Awada A; Kristeleit R; Olmedo ME; Wannesson L; Valdivia J; Rubio MJ; Anton A; Sarantopoulos J; Chawla SP; Mosquera-Martinez J; D'Arcangelo M; Santoro A; Villalobos VM; Sands J; Paz-Ares L
Lancet Oncol; 2020 May; 21(5):645-654. PubMed ID: 32224306
[TBL] [Abstract][Full Text] [Related]
5. Second-line lurbinectedin as a new treatment option for small-cell lung cancer: Preliminary results in real-clinical practice.
Toublanc AC; Guecamburu M; Veillon R; Rosellini P; Girodet PO; Zysman M
Thorac Cancer; 2022 Aug; 13(15):2248-2252. PubMed ID: 35715960
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study.
Olmedo ME; Forster M; Moreno V; López-Criado MP; Braña I; Flynn M; Doger B; de Miguel M; López-Vilariño JA; Núñez R; Kahatt C; Cullell-Young M; Zeaiter A; Calvo E
Invest New Drugs; 2021 Oct; 39(5):1275-1283. PubMed ID: 33704620
[TBL] [Abstract][Full Text] [Related]
7. Lurbinectedin in the treatment of relapsed small cell lung cancer.
Baena J; Modrego A; Zeaiter A; Kahatt C; Alfaro V; Jimenez-Aguilar E; Mazarico JM; Paz-Ares L
Future Oncol; 2021 Jun; 17(18):2279-2289. PubMed ID: 33736462
[TBL] [Abstract][Full Text] [Related]
8. Combination of cisplatin and lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma: Report of two cases.
Metaxas Y; Cathomas R; Mark M; von Moos R
Lung Cancer; 2016 Dec; 102():136-138. PubMed ID: 27440191
[TBL] [Abstract][Full Text] [Related]
9. Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval ≥30 days and without central nervous metastases.
Peters S; Trigo J; Besse B; Moreno V; Navarro A; Eugenia Olmedo M; Paz-Ares L; Grohé C; Antonio Lopez-Vilariño J; Fernández C; Kahatt C; Alfaro V; Nieto A; Zeaiter A; Subbiah V
Lung Cancer; 2024 Feb; 188():107448. PubMed ID: 38198859
[TBL] [Abstract][Full Text] [Related]
10. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
[TBL] [Abstract][Full Text] [Related]
11. Real-World Outcomes With Lurbinectedin in Second-Line Setting and Beyond for Extensive Stage Small Cell Lung Cancer.
Desai A; Smith CJ; Ashara Y; Orme JJ; Zanwar S; Potter A; Hocum C; Moffett JN; Schwecke AJ; Manochakian R; Lou Y; Zhao Y; Ernani V; Savvides P; Molina J; Dimou A; Mansfield AS; Parikh K; Leventakos K
Clin Lung Cancer; 2023 Dec; 24(8):689-695.e1. PubMed ID: 37880074
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment.
Subbiah V; Paz-Ares L; Besse B; Moreno V; Peters S; Sala MA; López-Vilariño JA; Fernández C; Kahatt C; Alfaro V; Siguero M; Zeaiter A; Zaman K; López R; Ponce S; Boni V; Arrondeau J; Delord JP; Martínez M; Wannesson L; Antón A; Valdivia J; Awada A; Kristeleit R; Olmedo ME; Rubio MJ; Sarantopoulos J; Chawla SP; Mosquera-Martinez J; D' Arcangelo M; Santoro A; Villalobos VM; Sands J; Trigo J
Lung Cancer; 2020 Dec; 150():90-96. PubMed ID: 33096421
[TBL] [Abstract][Full Text] [Related]
13. Lurbinectedin for the treatment of small cell lung cancer.
Li L; Zou C; Dong S; Wu ZX; Ashby CR; Chen ZS; Qiu C
Drugs Today (Barc); 2021 Jun; 57(6):377-385. PubMed ID: 34151904
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma.
Metaxas Y; Rivalland G; Mauti LA; Klingbiel D; Kao S; Schmid S; Nowak AK; Gautschi O; Bartnick T; Hughes BG; Bouchaab H; Rothschild SI; Pavlakis N; Wolleb S; Petrausch U; O'Byrne K; Froesch P; Löffler-Baumann M; Pratsch-Peter S; Russell P; Mingrone W; Savic S; Thapa B; Früh M; Pless M; von Moos R; John T
J Thorac Oncol; 2018 Nov; 13(11):1784-1791. PubMed ID: 30142389
[TBL] [Abstract][Full Text] [Related]
15. A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial.
Banna GL; Addeo A; Zygoura P; Tsourti Z; Popat S; Curioni-Fontecedro A; Nadal E; Shah R; Pope A; Fisher P; Spicer J; Roy A; Gilligan D; Gautschi O; Janthur WD; López-Castro R; Roschitzki-Voser H; Dafni U; Peters S; Stahel RA
Lung Cancer; 2022 Jul; 169():77-83. PubMed ID: 35660972
[TBL] [Abstract][Full Text] [Related]
16. Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study.
Fennell DA; Baas P; Taylor P; Nowak AK; Gilligan D; Nakano T; Pachter JA; Weaver DT; Scherpereel A; Pavlakis N; van Meerbeeck JP; Cedrés S; Nolan L; Kindler H; Aerts JGJV
J Clin Oncol; 2019 Apr; 37(10):790-798. PubMed ID: 30785827
[TBL] [Abstract][Full Text] [Related]
17. BAP1 gene mutations in Egyptian patients with advanced sporadic malignant pleural mesothelioma (MPM): relation with clinical outcomes and survival.
Bahnasy AA; El-Din RS; Sabri NA; Abdel-Rahman CA; Bastawisy AE
Cancer Genet; 2018 Dec; 228-229():83-92. PubMed ID: 30553477
[TBL] [Abstract][Full Text] [Related]
18. [Systemic Treatment of Malignant Pleural Mesothelioma].
Nakano T
Gan To Kagaku Ryoho; 2017 Dec; 44(13):2041-2047. PubMed ID: 29361614
[TBL] [Abstract][Full Text] [Related]
19. High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients.
Cantini L; Pecci F; Hurkmans DP; Belderbos RA; Lanese A; Copparoni C; Aerts S; Cornelissen R; Dumoulin DW; Fiordoliva I; Rinaldi S; Aerts JGJV; Berardi R
Eur J Cancer; 2021 Feb; 144():41-48. PubMed ID: 33326868
[TBL] [Abstract][Full Text] [Related]
20. Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study.
Cova E; Pandolfi L; Colombo M; Frangipane V; Inghilleri S; Morosini M; Mrakic-Sposta S; Moretti S; Monti M; Pignochino Y; Benvenuti S; Prosperi D; Stella G; Morbini P; Meloni F
Int J Nanomedicine; 2019; 14():773-785. PubMed ID: 30774332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
